|
2025
|
Invention
|
Scaffold proteins.
The invention relates to a polypeptide, such as an Affimer polypeptide, compr... |
|
|
Invention
|
Polypeptides and methods for detecting and quantifying small molecules. The present disclosure pr... |
|
2024
|
Invention
|
Scaffold proteins. The invention relates to a polypeptide, such as an Affimer polypeptide, compri... |
|
2023
|
Invention
|
Tnfr2 binding polypeptides and methods of use. The present disclosure relates to engineered TNFR2... |
|
|
Invention
|
Lag-3/pd-l1 binding fusion proteins. The present disclosure provides engineered bispecific LAG-3/... |
|
2022
|
Invention
|
Pd-l1 binding affimers.
The present disclosure relates to engineered PD-L1-binding Stefin A poly... |
|
|
Invention
|
Serum half-life extended pd-l1 binding polypeptides.
The present disclosure provides engineered ... |
|
|
Invention
|
Pd-l1 binding affimers. The present disclosure relates to engineered PD-L1 -binding Stefin A poly... |
|
|
Invention
|
Serum half-life extended pd-l1 binding polypeptides. The present disclosure provides engineered P... |
|
|
Invention
|
Cd33 binding polypeptides with stefin a protein. The present disclosure relates to engineered CD3... |
|
2021
|
Invention
|
Fap-activated serum extended half-life therapeutic conjugates.
Disclosed herein are therapeutic ... |
|
|
Invention
|
Enzyme-activated serum extended half-life therapeutic conjugates.
Disclosed herein are therapeut... |
|
|
Invention
|
Fap-activated serum extended half-life therapeutic conjugates. Disclosed herein are therapeutic c... |
|
|
Invention
|
Enzyme activated serum extended half-life therapeutic conjugates. Disclosed herein are therapeuti... |
|
|
Invention
|
Serum albumin-binding polypeptides.
Provided herein, in some embodiments, are recombinantly engi... |
|
|
Invention
|
Serum half-life extended pd-l1 inhibitory polypeptides.
Provided herein, in some embodiments, ar... |
|
|
Invention
|
Serum half-life extended pd-l1 inhibitory polypeptides. Provided herein, in some embodiments, are... |
|
|
Invention
|
Serum albumin-binding polypeptides. Provided herein, in some embodiments, are recombinantly engin... |
|
|
Invention
|
Sars-cov2 diagnostic polypeptides and methods. 3,22; wherein said polypeptide further comprises a... |
|
2020
|
Invention
|
Bispecific anti-pd-l1 and anti-fcrn polypeptides. Provided herein, in some embodiments, are bispe... |
|
|
Invention
|
Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties.. The present disclosure is directed to... |
|
2019
|
Invention
|
Tumor microenvironment-activated drug-binder conjugates, and uses related thereto.
Disclosed are... |
|
|
Invention
|
Tumor microenvironment-activated drug-binder conjugates, and uses related thereto. Disclosed are ... |
|
|
Invention
|
Pd-l1 binding affimers, and uses related thereto.
The present disclosure relates to proteins inc... |
|
|
Invention
|
Pd-l1 binding affimers, and uses related thereto. The present disclosure relates to proteins incl... |
|
|
Invention
|
Pd-l1 binding affimers and uses related thereto. (12) INTERNATIONAL APPLICATION PUBLISHED U... |
|
2014
|
Invention
|
Modified stefin a scaffold proteins. The invention provides novel scaffold proteins for the displ... |
|
2009
|
Invention
|
Modified stefin a scaffold proteins. The invention provides novel scaffold proteins for the... |
